MARKETS & INVESTING
The confidence in the US economy is understandable given that there has been no economic recession for 15 years
abnormal profits first attract abnormal speculation and then abnormal competition . Moreover , there ’ s an inherent cyclicality of demand for capital expenditure beneficiaries – whatever today ’ s trend might be – as shown by the history of massive 50 % - 90 % drawdowns in Nvidia ’ s otherwise very successful history , in 2002 , 2008 , 2018 and 2022⁴ . For the avoidance of doubt , we are not making a bear case for Nvidia here ; there is plenty of potential upside . It is just that there is plenty of potential downside as well , and the market seems more focussed on the former at present . It is this very wide range of outcomes that excludes us from owning Nvidia . Our strategies do embrace change and evolve significantly over time – our flagship global strategy ’ s consumer staples weight has gone from over 60 % to under 20 % over the past decade , and information technology is now over a quarter of the portfolio , even excluding the stocks that the Global Industry Classification Standard , known as GICS , moved into other sectors last year . However , we continue to look for the same characteristics since our strategy launched : strong intangible assets delivering high returns and pricing power , recurring revenues and decent , resilient growth , all at a reasonable valuation . We have also reflected on some important lessons , most notably in consumer staples and healthcare . We shall aim to be less patient where larger holdings underdeliver on earnings while overdelivering on negative surprises , even if their valuations appear to be supportive . Also , we recognise we need to be more wary of transformational acquisitions , especially if they may be covering up existing problems in the core business . Our portfolio composition has continued to evolve , from companies with powerful strongholds in dental care and painkillers to medtech for burgeoning women ’ s health services , innovative life sciences that support medical discovery , digital music , leading data companies set to benefit from AI and the enterprise staples of our era – cloud-based software as a service , data , payments and insurance broking . We believe these should deliver a portfolio offering resilient revenue growth and faster earnings growth at a reasonable valuation , with a free cash flow yield close to that of the market , with a history of double-digit compounding achieved over the last quarter of a century . The current index composition and economic sailing conditions have made it challenging to deliver strong relative performance . We remain steadfast in following our quality process and our focus on
40 | the adviser